1453083-76-5

Upstream product

• 17133-16-3 ethyl 2,2-diethyl-4-pentenoate 
• 827017-69-6 3,3-diethyl-4,5-dihydro-5-(2-hydroxyethyl)-2(3H)-furanone 
• 827017-71-0 2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl-4-methylbenzenesulfonate 
• 38212-30-5 4-(4-methoxyphenyl)piperazine 
• 1193397-45-3 6,6-diethyl-7-oxooxepan-4-yl acetate 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel, selective γ-butyrolactones sigma-2 ligands

Nearly 40 years after the first disclosure of sigma receptors, the sigma-2 (σ2) receptor was recently identified as the Transmembrane Protein 97 (TMEM97, also known as MAC30 (Meningioma-associated protein). This macromolecule has been associated with a nu

NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.

Homologation as a lead modification approach en route to a series of lactone-based muscarinic ligands

Previous work identified the lactone ring as a useful scaffold for the design of muscarinic ligands and reported a lactone-based ligand with an IC 50 of 340 nM. Using homologation as a lead modification approach, a new series of lactone-based c

NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE

Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.